Tirzepatide
Category: Dual GIP/GLP-1 Agonist
A dual GIP and GLP-1 receptor agonist showing superior weight loss compared to semaglutide.
Half-Life: 120 hours
Common Dosage: 2.5mg
Benefits
- Superior weight loss (15-22% body weight)
- Excellent blood sugar control
- Improved lipid profiles
- Reduced cardiovascular risk
- Better appetite suppression than GLP-1 alone
- Improved insulin sensitivity
Side Effects
- Nausea and vomiting
- Diarrhea
- Decreased appetite
- Constipation
- Indigestion
- Fatigue